Ronda Stryker Sells 250,000 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Stryker Stock Performance

Stryker stock opened at $358.49 on Friday. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $137.09 billion, a P/E ratio of 42.68, a PEG ratio of 2.10 and a beta of 0.87. The stock has a fifty day moving average price of $358.39 and a 200 day moving average price of $370.68. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The company had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. Stryker’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the business earned $4.01 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is 41.90%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC lifted its position in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares during the last quarter. Simplicity Wealth LLC acquired a new position in shares of Stryker in the 2nd quarter valued at $464,000. BankPlus Trust Department raised its position in Stryker by 425.7% in the second quarter. BankPlus Trust Department now owns 389 shares of the medical technology company’s stock worth $154,000 after purchasing an additional 315 shares in the last quarter. Sax Wealth Advisors LLC raised its holdings in shares of Stryker by 329.6% in the 2nd quarter. Sax Wealth Advisors LLC now owns 2,638 shares of the medical technology company’s stock worth $1,044,000 after buying an additional 2,024 shares in the last quarter. Finally, REAP Financial Group LLC raised its stake in Stryker by 90.4% during the second quarter. REAP Financial Group LLC now owns 139 shares of the medical technology company’s stock worth $55,000 after acquiring an additional 66 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on SYK shares. Needham & Company LLC increased their price target on shares of Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. UBS Group set a $408.00 price target on shares of Stryker in a research report on Monday, October 13th. Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Robert W. Baird set a $437.00 target price on shares of Stryker in a research note on Friday, January 30th. Finally, Truist Financial reduced their target price on Stryker from $400.00 to $392.00 and set a “hold” rating for the company in a report on Thursday, December 18th. Twelve equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $426.94.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.